SavedAdd your journal

Journals / Selçuk Tıp Dergisi / 2007 / Cilt: 23 - Sayı: 3

Axon loss in multiple sclerosis

Multipl sklerozda akson kaybı

Zehra AKPINAR
Aysun Hatice AKÇA
Pages
151–156
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However therapies are also needed that enhance remyelination or neuroprotective.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system.
📊
Key Findings & Data:Recent evidence, however, demonstrates that axonal loss is also significant, affects long tracts such as the corticospinal and sensory tracts and relates closely to functional disability.
💡
Conclusion & Impact:However therapies are also needed that enhance remyelination or neuroprotective.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Multipl skleroz · Aksonlar · Wallerian Dejenerasyonu

Abstract

Aim: Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system. Clinical, imaging, and pathological studies in multiple sclerosis have generally emphasized the relative preservation of axons in comparison with myelin. Recent evidence, however, demonstrates that axonal loss is also significant, affects long tracts such as the corticospinal and sensory tracts and relates closely to functional disability. In this article we will consider emerging observations that reflect on the mechanisms of axon loss. Main Findings: There are different mechanisms of axon loss occur. Mechanisms of axon loss: Axonal damage in the inflammation, demyelination- induced axon loss, wallerian degeneration, and final common pathway in the axon loss. Conclusion: Axon loss is irreversible and responsible for long term disability. However therapies are also needed that enhance remyelination or neuroprotective.

Özet

Amaç: Multiple Skleroz (MS), santral sinir sisteminin inflamatuvar demiyelinizan hastalığıdır. MS'de klinik, görüntüleme ve patolojik çalışmalar genel olarak miyelinle kıyaslandığında aksonun relatif olarak korunduğunu vurgulamaktadır. Bununla birlikte son kanıtlar, anlamlı akson kaybının da olduğunu, kortikospinal, sensoriyel traktlar gibi uzun traktların etkilediğini ve fonksiyonel sakatlıkla yakın ilişkili olduğunu göstermektedir. Bu makalede biz akson kaybı mekanizmalarını vurgulayacağız. Ana Bulgular: Akson kaybı gelişiminin farklı mekanizmaları vardır. Akson kaybı mekanizmaları: inflamasyonda aksonal hasar, demiyelinizasyon aracılı aksonal kayıp, vvallerian dejenerasyon (WD) ve akson kaybında ortak son yol olarak sınıflandırılabilir. Sonuç: Akson kaybı geri dönüşsüz ve uzun dönemde sakatlık nedenidir. Tedaviler remiyelinizasyon veya nöroprotektiyon gerektirir.

🔖

Cite This Article

AKPINAR, Z., AKÇA, A. H. (2007). Axon loss in multiple sclerosis. Selçuk Tıp Dergisi, Cilt: 23 - Sayı: 3, 151–156. https://ajindex.com/articles/319164

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Bjartmar C, Yin X, Trapp BD. Axonal pathology in myelin disorders. J Neurocytol 1999; 28: 383-95
  2. Como L. Neuroprotection in multiple sclerosis. MS forum Mach 2004 Workshop
  3. Lassmann H, Bruck W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis implications for diagnosis and therapy. Trends Mol Med 2001;7:1 15- 21
  4. Lassmann H. Mechanisms of demyelination and tissue destruction in multiple sclerosis. Clin Neurol Neurosurg 2002; 104: 168- 71
  5. Trapp BD, Peterson J, Ransohott R. Axonal transsection in the lesions of multiple sclerosis. New Eng J Med 1998; 338: 278-85
  6. Miller DH, Barkhof F, Frank JA, Parker GJ, Thompson AJ. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 2002; 125: 1676-95
  7. DeLuca GC, Ebers GC, Esiri MM. Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts. Brain 2004; 127: 1009-18
  8. Ferguson B, Mafyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120: 393-9
  9. Hendriks JJ, Teunissen CE, de Vries HE, Dijkstra CD. Macrophages and neurodegeneration. Brain Res Rev 2005; 48:185-95
  10. Halfpenny C, Benn T, Scolding N. Cell translantation, myelin repair, and multiple sclerosis. Lancet Neurol 2002; 1:31-40
  11. Gonen O, Catalaa I, Babb JS. Total brain N-acetylaspartate: a new measure of disease load in MS. Neurology 2000; 54: 15-9
  12. Rovaris M, Gallo A, Falini A, Benedetti B, Rossi P, Comola M, Scotti G, Comi G, Filippi M. Axonal injury and overall tissue loss are not related in primary progressive multiple sclerosis. Arch Neurol 2005; 62: 898-902
  13. Paolillo A Piattella MC, Pantano P. The relationship between inflamation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis. A monthyl MRI study after triple-dose gadolinium-DTRA. J Neurol 2004; 251: 432- 9
  14. Rieckmann P. Neurodegeneration and clinical relevance for early treatment in multiple sclerosis. Int MS J 2005; 12:42-51
  15. Bruck W. Inflammatory demyelination is not central to the pathogenesis of multiple sclerosis. J Neurol 2005; 252 Suppl 5:v 10-5
  16. Chao CC, Hu S. Tumor necrosis factor-alpha potentiates glutamate neurotoxicity in human fetal brain cell cultures. Dev Neurosci 1994; 16: 172-9
  17. Hensley K, Robinson KA, Gabbita SP, Salsman S, Floyd RA. Reactive oxygen species, cell signaling, and cell injury. Free Radic Biol Med 2000; 28: 1456-62
  18. Nimnual AS, Ta